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	 A	 series	 of	 six	 pyrazoline	 ring	 derivatives	 as	 a	 pharmacophore	 were	 incorporated	 to	 the
naproxen;	 to	 increase	 its	 size	 were	 synthesized	 and	 preliminarly	 evaluated	 as	 anti‐
inflammatory	 agents	 with	 expected	 selectivity	 toward	 COX‐2	 enzyme.	 In	 vivo	 acute	 anti‐
inflammatory	 effects	 of	 the	 final	 compounds	 (5a‐f)	 were	 evaluated	 in	 rats	 using	 egg‐white
induced	 edema	 model	 of	 inflammation.	 The	 tested	 compounds	 and	 the	 reference	 drug
(naproxen)	produced	significant	reduction	of	paw	edema	with	respect	to	the	effect	of	control
group	(propylene	glycol	50%,	v:v).	However,	compound	5d	and	5e	show	comparable	effect	to
naproxen	 at	 all	 experimental	 time	 while	 compounds	 5a,	 5b	 and	 5c	 produced	 significantly
lower	 inhibitory	 effect	 than	naproxen	at	 time	120‐240	minutes.	 Furthermore,	 compound	5f
exert	 significantly	 higher	 paw	 edema	 reduction	 than	 naproxen	 at	 60‐240	 min.	 Also	 the
antibacterial	activities	of	 the	 final	 compounds	were	evaluated	by	Well	Diffusion	Method.	All
tested	 compounds	 exert	 significant	 antibacterial	 activity	 against	 tested	 Gram	 positive	 and
Gram	negative	bacteria	in	comparison	to	dimethyl	sulfoxide	as	control	group.	In	comparison
the	 antibacterial	 results	 among	 the	 tested	 compound	 5e	 may	 regard	 the	 best	 one	 and
compound	5c		the	lower	one.	
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1.	Introduction	
	
Non‐steroidal	 anti‐inflammatory	 drugs	 (NSAIDs)	 are	
among	the	most	widely	used	medications	in	the	world,	owing	
to	 their	 analgesic,	 anti‐inflammatory	 and	 antipyretic	 proper‐
ties	 [1,2].	 Recent	 years,	 epidemiological	 study	 indicates	 that	
NSAIDs	are	neuroprotective	[3].	Thus,	prolong	used	reduce	the	
risk	of	Alzheimer	[4].	
Furthermore,	clinical	study	provides	evidence	that	NSAIDs	
derivatives	 are	promising	 anticancer	drugs	 [5].	However,	 the	
use	 of	 “traditional”	 NSAIDs	 results	 in	 serious	 upper	 gastro‐
intestinal	(GI)	adverse	events	in	nearly	one	fourth	of	patients	
[6].	 The	 most	 common	 side	 effects	 are	 the	 propensity	 of	
NSAIDs	 to	 induce	 gastric	 or	 intestinal	 ulceration.	 Thus,	
patients	 who	 use	 NSAIDs	 on	 chronic	 basis	 have	 about	 three	
times	 greater	 relative	 risk	 for	 serious	 adverse	 GI	 events	
compared	to	the	population	of	non‐user	[7,8].	Therefore,	there	
is	 a	 need	 for	 anti‐inflammatory	and	 analgesic	drugs	 that	will	
provide	 symptom	 relief	 without	 causing	 GI	 injury	 [9].	 The	
NSAIDs	 are	 chemically	 diverse,	 most	 being	 organic	 acids,	
despite	 their	 structural	 heterogeneity,	 NSAIDs	 possess	 a	
common	mode	of	action,	which	block	prostaglandin	synthesis	
largely	 though	 their	 inhibition	of	 the	enzyme	cyclooxygenase	
(COX),	which	 catalyze	 the	 transformation	 of	 arachidonic	 acid	
to	prostaglandins	and	thromboxane	[10].	Three	different	COX	
enzymes	existed,	known	as	COX‐1,	COX‐2	and	COX‐3	[11].	
COX‐1	is	a	constitutive	isoform	found	in	most	normal	cells	
and	 tissues	 [12].	 It	 is	 stimulated	 by	 growth	 factor	 and	
hormones	 and	 it	 has	 been	 called	 the	 housekeeping	 enzyme	
[13].	The	COX‐1	plays	 fundamental	 roles	 in	 the	generation	of	
PGs	 in	 homoeostasis	 [14]	 and	 several	 other	 physiological	
functions	 including	 gastric	 protection	 and	 control	 of	 renal	
blood	flow	[15].	
COX‐2	 is	 the	 readily	 inducible	 form	of	 the	 enzyme	and	 is	
commonly	 associated	 with	 several	 pathological	 conditions.	
COX‐2	 is	 found	 in	 the	 heart	 [16],	 spinal	 cord	 [17],	 vascular	
endothelium,	 brain,	 kidney,	 bone	 and	 female	 reproductive	
system.	 It’s	 also	 involved	 in	 certain	 physiological	 processes	
[18,19].	However,	 it	 is	 induced	by	 inflammatory	 stimuli	 such	
as	bacterial	endotoxin	and	cytokines	[19,20].	 Increased	levels	
of	COX‐2	have	also	been	seen	in	diseases	such	as	Alzheimer’s	
disease,	 systemic	 lupus	 erythematous,	 colon,	 breast	 and	
pancreatic	 cancer,	 as	 well	 as	 diabetic	 neuropathy	 and	
premature	labor	[18,21].	Selective	COX‐2	inhibitors	differ	from	
traditional	NSAIDs	in	two	major	ways,	Coxibs	are	less	likely	to	
result	 in	 NSAID‐induced	 gastropathy	 and	 they	 do	 not	 inhibit	
platelet	function	[22].	As	a	result,	the	major	benefits	of	coxibs	
are	the	reduction	in	gastric	ulcer	formation	and	bleeding	from	
those	ulcers	[23].	
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Figure	1.	Difference	between	COX‐1	and	COX‐2	is	in	size	of	active	center	[31].
	
	
Another	benefit	of	 the	platelet	 sparing	coxibs	 is	 their	use	
as	 analgesic	 and	 anti‐inflammatory	 agents	 in	 situations	 in	
which	 bleeding	 may	 limit	 the	 use	 of	 the	 traditional	 NSAIDs,	
such	as	in	trauma	and	surgical	procedures	[24,25].	
There	 are	 numerous	 biologically	 active	 hetrocycles	
molecules	 bearing	 nitrogen,	 sulphur	 and	 oxygen,	 always	
drawn	 the	 attention	 over	 the	 years	 mainly	 because	 of	 their	
biological	 importance	 [26].	 Pyrazoline	 is	 five‐membered	
heterocyclic	 and	 their	 derivatives	 have	 been	 found	 to	 have	
diverse	pharmacological	activities	such	as	anticonvulsant,	anti‐
inflammatory,	 antimicrobial,	 antiviral,	 anticancer,	 anti‐
helicobacter	 pylori,	 antitubercular,	 antiamoebic,	 antiandro‐
genic,	 hypotensive,	 and	 antihistaminic,	 antidiabetic,	 analgesic	
and	antipyretic	action	[27,28].	
The	direction	of	the	present	work	is	to	synthesis	potential	
non‐steroidal	anti‐inflammatory	agents	that	are	derivatives	of	
naproxen	 by	 incorporating	 a	 group	 of	 pyrazoline	 pharma‐
cophore	in	the	carboxylate	group	of	naproxen.	Then	evaluated	
them	 as	 anti‐inflammatory	 and	 antibacterial	 agents.	 These	
newly	 synthesized	 compounds	 may	 represent	 potent	 anti‐
inflammatory	agents	and	exhibit	expected	selectivity	towards	
COX‐2	enzyme	due	to	their	large	size	than	its	parent	naproxen	
compound	 and	 the	 fact	 of	 presence	 the	 side	 pocket	 near	 the	
base	 of	 the	 active	 site	 of	 COX‐2	 enzyme	makes	 its	 site	 20%	
larger	than	that	of	COX‐1	[29]	so	the	active	center	of	COX‐2	can	
accommodate	larger	structures	than	those	which	are	able	to	fit	
the	active	site	of	COX‐1	[30]	as	shown	in	Figure	1	[31].	
	
2.	Experimental	
	
2.1.	Reagents	and	instrumentation	
	
All	 reagents	 and	anhydrous	solvents	were	of	 analar	 type,	
were	purchased	 from	(Fluka,	Switzerland,	Avochem,	England,	
Himedia,	 India,	 Sigma‐Aldrich,	 Germany	 and	 BDH,	 England).	
Naproxen	 was	 a	 product	 of	 the	 General	 Company	 for	
Pharmaceutical	 Industries	 and	 Medical	 Appliances,	 Samarra,	
Iraq.		
Electro	 thermal	 melting	 point	 apparatus	 and	 open	
capillary	tubes	were	used	to	determine	the	melting	points	and	
are	uncorrected.	Thin	 layer	 chromatography	was	 run	on	TLC	
silica	gel	(60)	F254,	Merck	(Germany),	for	checking	the	purity	of	
the	 products	 as	 well	 as	 monitoring	 the	 progress	 of	 the	
reaction.	 Chromatograms	were	 eluted	 by	 using	 two	 different	
solvent	systems:	A:	Benzene:carbon	tetrachloride:ethyl	acetate	
(50:40:10,	 v:v:v).	 B:	 Chloroform:methanol	 (85:15,	 v:v).	
Compounds	were	 revealed	upon	 irradiation	with	UV	 light.	 IR	
spectra	 were	 recorded	 on	 a	 FTIR,	 Shimadzu	 8100s	 spectro‐
meter	 as	KBr	 disks	 in	 College	 of	 Pharmacy,	 Al‐Mustansiriyah	
University.	 1H	 NMR	 spectra	 were	 recorded	 on	 Bruker	 500	
MHz‐Avance	III	in	University	of	Jordan,	Faculty	of	Science,	and	
Department	 of	 Chemistry,	 Jordan.	 CHNS	 microanalysis	 was	
done	using	a	Euro‐Vector	EA3000	(Italy)	in	College	of	Science,	
Al‐Mustansiriyah	University,	Baghdad,	Iraq.	The	general	routes	
outlined	in	Scheme	1	were	used	to	synthesize	all	compounds.	
	
2.1.1.	General	procedure	for	synthesis	of	chalcone	
derivatives	(1a‐f)	
	
Acetophenone	 (1.18	 mL,	 10	 mmole)	 and	 aromatic	
aldehyde	derivatives	(a‐f)	(10	mmole)	were	added	to	ethanol	
(22	mL),	 then	 sodium	hydroxide	 (40%,	 10	mL)	 solution	was	
added	drop	wise	over	2	min.	The	mixture	was	irradiated	by	an	
ultrasonic	 generator	 in	 a	water	 bath	 at	 30‐35	 °C	 for	 25	min,	
turbidity	appeared	in	the	mixture,	which	was	then	neutralized	
with	2	N	HCl.	The	solid	product	 formed	was	 filtered,	washed	
with	cold	water	and	recrystallized	by	ethanol	[32,33],	Table	1.	
1,3‐Diphenylpropenone	 (1a):	 Color:	 Pale	 yellow	 crystals.	
Yield:	94%.	M.p.:	56‐58	°C.	Rf:	A	=	0.52,	B	=	0.39.	FT‐IR	(KBr,	ν,	
cm‐1):	1660	 (C=O),	1603,	1573	 (C=C	aromatic).	 1H	NMR	 (500	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 7.45‐7.96	 (m,	 10H,	 Ar‐H),	 8.16‐8.18	
(m,	 2H,	 CH=CH).	 Anal.	 calcd.	 for	 C15H12O:	 C,86.51;	 H,	 5.81.	
Found:	C,86.70;	H,5.65%.	
3‐(4‐Chlorophenyl)‐1‐phenylprop‐2‐en‐1‐one	 (1b):	 Color:	
Off	white	crystals.	Yield:	78%.	M.p.:	112‐114	°C.	Rf:	A	=	0.57,	B	
=	 0.46.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1660	 (C=O),	 1658,	 1603	 (C=C	
aromatic),	 821	 (C‐Cl).	 Anal.	 calcd.	 for	 C15H11ClO:	 C,	 74.23;	 H,	
4.57.	Found:	C,	74.12;	H,	4.69%.	
3‐(4‐Nitrophenyl)‐1‐phenylprop‐2‐en‐1‐one	 (1c):	 Color:	
Orange	powder.	Yield:	70%.	M.p.:	159‐161	°C.	Rf:	A	=	0.46,	B	=	
0.36.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1660	 (C=O),	 1603	 (C=C	 aromatic),	
1516	 (NO2	 asymmetric),	 1336	 (NO2	 symmetric).	 Anal.	 calcd.	
for	 C15H11NO3:	 C,	 71.14;	 H,	 4.38;	 N,	 5.53.	 Found:	 C,	 71.77;	H,	
4.29;	N,	5.68%.	
3‐(4‐Hydroxyphenyl)‐1‐phenylprop‐2‐en‐1‐one	 (1d):	 Color:	
Green‐yellowish	powder.	Yield:	67%.	M.p.:	182‐184	°C.	Rf:	A	=	
0.81,	 B	 =	 0.65.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1649	 (C=O),	 1599,	 1558	
(C=C	aromatic),	1348	(O‐H),	1215	(C‐OH).	1H	NMR	(500	MHz,	
DMSO‐d6,	 δ,	 ppm):	 6.86‐7.75	 (m,	 9H,	 Ar‐H),	 8.12‐8.13	 (d,	 2H,	
CH=CH).	Anal.	calcd.	 for	C15H12O2:	C,	80.34;	H,	5.39.	Found:	C,	
81.22;	H,	5.28%.	
3‐(4‐Methoxyphenyl)‐1‐phenylprop‐2‐en‐1‐one	 (1e):	 Color:	
Pale	yellow	crystals.	Yield:	75%.	M.p.:	73‐75	°C.	Rf:	A	=	0.54,	B	
=	0.44.	FT‐IR	(KBr,	ν,	cm‐1):	1657	(C=O),	1601	and	1574	(C=C	
aromatic),	 1263	 (C‐OCH3).	 1H	 NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	
ppm):	3.82	 (s,	 3H,	 ‐OCH3),	7.45‐7.96	 (m,	9H,	Ar‐H),	8.16‐8.18	
(d,	 2H,	 CH=CH).	 Anal.	 calcd.	 for	 C16H14O2:	 C,	 80.65;	 H,	 5.92.	
Found:	C,	79.21;	H,	5.96%.	
3‐(4‐(Dimethyl	 amino)	 phenyl)‐1‐phenylprop‐2‐en‐1‐one	
(1f):	Color:	Orange	crystals.	Yield:	80%.	M.p.:	111‐113	°C.	Rf:	A	
=	0.59,	B	=	0.49.	FT‐IR	(KBr,	ν,	cm‐1):	1649	(C=O),	1599,	1562	
(C=C	aromatic),	1172	(N‐CH3).	1H	NMR	(500	MHz,	DMSO‐d6,	δ,	
ppm):	3.02	(s,	6H,	N(CH3)2),	6.75‐7.72	(m,	9H,	Ar‐H),	8.10‐8.11	
(m,	2H,	CH=CH).	Anal.	calcd.	for	C17H17NO:	C,	81.24;	H,	6.82;	N,	
5.57.	Found:	C,	83.13;	H,	7.03;	N,	5.85%.	
	
2.1.2.	Synthesis	of	ethyl	amino	acetate	hydrochloride	(2)	
	
Thionyl	chloride	(0.8	mL,	11	mmole)	was	added	gradually	
to	 absolute	 ethanol	 (10	mL)	 cooled	 to	 (0	 °C).	 2‐Aminoacetic	
acid	(0.75	g,	10	mmol)	was	suspended	in	the	reaction	mixture	
and	subjected	to	ultra‐sonication	at	room	temperature	for	45	
min.	
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Scheme	1
	
	
On	 completion	 of	 the	 reaction,	 the	 solvent	 was	 removed	
under	 reduced	 pressure	 and	 the	 residue	 was	 purified	 by	
recrystallization	 from	 methanol:	 diethyl	 ether	 [34].	 Color:	
White	crystals.	Yield:	90%.	M.p.:	145‐147	°C.	Rf:	A	=	0.55,	B	=	
0.48.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1748	 (C=O	 ester),	 1250	 (C‐O‐C	
ester),	1172	(N‐CH3).	Anal.	calcd.	for	C4H10ClNO2:	C,	34.42;	H,	7.	
22;	N,	10.03.	Found:	C,	33.65;	H,	7.16;	N,	10.32%.	
	
2.1.3.	Synthesis	of	(2S)‐ethyl‐2‐[2‐(6‐methoxynaphthalen‐2‐
yl)‐propanamido]	acetate	(3)	
	
Compound	2	 (2.8	 g,	 20	mmole),	 triethylamine	 (3	mL,	 21	
mmole)	and	naproxen	(4.6	g,	20	mmole)	were	dissolved	in	dry	
dichloromethane	 (DCM)	 (40	 mL).	 The	 reaction	 mixture	 was	
stirred	at	0	 °C	 for	30	min.To	 this	 solutiondicyclohexyl	 carbo‐
diimide	 (DCC)	 (4.13	 g,	 20	mmole)	 in	 dry	 DCM	 (10	mL)	 was	
added	 slowly	 in	 a	 drop	 wise	 manner.	 Reaction	 mixture	 was	
stirred	 for	 3	 days	 at	 0	 °C.	 Precipitated	 dicyclohexylurea	was	
filtered	 off	 and	 the	 solvent	 was	 distilled	 off	 under	 reduced	
pressure.	The	product	obtained	was	dissolved	in	ethyl	acetate	
(30	mL)	and	filtered.	Ethyl	acetate	layer	was	washed	with	10%	
aqueous	 solution	 of	 sodium	 bicarbonate	 (3×30	 mL)	 and	
distilled	water	(3×30	mL).	Ethyl	acetate	 layer	was	dried	with	
anhydrous	 magnesium	 sulphate	 and	 filtered	 to	 get	 a	 clear	
solution	 of	 product	 in	 ethyl	 acetate.	 Solvent	 was	 evaporated	
under	reduced	pressure	and	the	crude	product	was	recrystal‐
lized	 by	 using	 hexane:	 ethyl	 acetate	 [35].	 Color:	 Off	 White	
powder.	Yield:	65%.	M.p.:	84‐86	°C.	Rf:	A	=	0.66,	B	=	0.55.	FT‐IR	
(KBr,	ν,	 cm‐1):	3293	(NH	amid),	1740	(C=O	ester),	1649	(C=O	
amide).	 1H	 NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.14	 (t,	 3H,	
OCH3	ester),	1.24‐1.26	(d,	3H,	CH3	naproxen),	3.80‐3.84	(m,	3H,	
CH	naproxen	 and	CH2	 glycine),	 3.87	 (s,	 3H,	 ‐OCH3	naproxen),	
4.04‐4.08	(q,	2H,	CH2	ester),	7.14‐7.79	(m,	6H,	Ar‐H),	8.40	(br.	
s,	1H,	NH	amide).		Anal.	calcd.	for	C18H21NO4:	C,	68.55;	H,	6.	71;	
N,	4.44.	Found:	C,	69.61;	H,	6.79;	N,	4.59%.	
	
2.1.4.	Synthesis	of	(2S)‐N‐(2‐hydrazinyl‐2‐oxoethyl)‐2‐(6‐
methoxy‐naphthalen‐2‐yl)	propanamide	(4)	
	
Compound	3	 (1.00	 g,	 3	 mmole)	 was	 dissolved	 in	 15	mL	
methanol	 and	 hydrazine	 hydrate	 (90%)	 (0.7	mL,	 14	mmole)	
was	 added.	 The	 reaction	 mixture	 was	 stirred	 at	 room	
temperature	overnight.	On	the	next	day,	 the	solvent	has	been	
removed	under	 reduced	pressure	and	 the	crude	product	was	
washed	with	ether	under	stirring	to	afford	the	product	in	pure	
state	[35].	Color:	Yellow	powder.	Yield:	78%.	M.p.:	158‐160	°C.	
Rf:	 A	 =	 0.75,	 B	 =	 0.50.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3339	 and	 3277	
(NHNH2),	 1678(C=Oamidic),	 1645(C=Oamide).	 1H	 NMR	 (500	
MHz,	DMSO‐d6,	δ,	ppm):	1.41‐1.42	(d,	3H,	CH3	naproxe),	3.55‐
3.73	(d,	2H,	CH2	glycine),	3.81‐3.87	(q,	1H,	CH	naproxen),	3.90	
(s,	3H,	‐OCH3	naproxen),	4.20	(br.	s,	2H,	NH2	hydrazide),	7.13‐
7.83	 (d,	6H,	Ar‐H),	8.20	(br.	s,	1H,	NH	amide),	9.01(s,	1H,	NH	
hydrazide).	 Anal.	 calcd.	 for	 C16H19N3O3:	 C,	 63.77;	 H,	 6.	 36;	 N,	
13.94.	Found:	C,	62.89;	H,	6.25;	N,	14.04%.	
	
2.1.5.	General	procedure	for	synthesis	of	(2S)‐N‐(2‐(3,5‐
diaryl‐4‐5‐dihydro‐1H‐pyrazol‐1‐yl)‐2‐oxoethyl)‐2‐(6‐
methoxynaphthalen‐2‐yl)	propanamid	(5a‐f)	
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Table	1.	Aromatic	aldehyde’s	name	and	products.	
Compound	 Aldehyde	 Products	No	 R	 Quantity	(g)	
a	 Benzaldehyde	 1a H 1.06	
b	 4‐Chlorobenzaldehyde	 1b Cl 1.40	
c	 4‐Nitrobenzaldehyde	 1c	 NO2	 1.51	
d	 4‐Hydroxybenzaldehyde	 1d	 OH	 1.22	
e	 4‐methoxybenzaldehyde	 1e	 OCH3	 1.36	
f	 4‐Dimethylaminobenzaldehyde	 1f	 N(CH3)2	 1.49	
	
	
The	product	has	been	synthesized	by	dissolving	a	mixture	
of	one	chalcone	derivatives	(1a‐f)	(1	mmole)	and	compound	4	
(0.30	 g,	 1	 mmole)	 in	 20	 mL	 of	 ethanol,	 after	 15	 min,	 the	
mixture	 has	 been	 refluxed.	 A	 catalytic	 glacial	 acetic	 acid	 has	
been	added	and	the	contents	allowed	to	be	refluxed	for	24	hrs.	
The	reaction	time	was	considered	by	performing	TLC	to	obtain	
single	 spot.	 The	 reaction	 mixture	 has	 been	 cooled	 and	
transfers	it	in	to	20	mL	of	cold	water	in	order	to	precipitate	the	
product.	 The	 product	 has	 been	 washed	 twice	 in	 cold	 water,	
filtered	and	 then	dried.	After	 that,	 the	 re‐crystallized	process	
has	been	done	from	hot	ethanol.	
(2S)‐N‐(2‐(3,5‐Diphenyl‐4,5‐dihydro‐1H‐pyrazol‐1‐yl)‐2‐oxo	
ethyl)‐2‐(6‐methoxynaphthalen‐2‐yl)	propanamide	 (5a):	 Color:	
Off	white	powder.	Yield:	70%.	M.p.:	68‐70	°C.	Rf:	A	=	0.61,	B	=	
0.49.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3296	 (NH	 amide),	 1653	 (C=O	
amide),	1604	(C=C	Aromatic),	1533	(C=N	amide),	1267	(Ar‐O‐
C).	1H	NMR	(500	MHz,	DMSO‐d6,	δ,	ppm):	1.41‐1.43	(d,	3H,	CH3	
naproxe),	 3.49‐3.73	 (m,	 3H,	 CH2	 pyrazoline	 and	 CH	 of	
naproxen),	 3.86	 (s,	 3H,	 ‐OCH3	 naproxen),	 4.23	 (br.s,	 2H,	 CH2	
glycine	),	5.28	(br.	s,	1H,	CH	pyrazoline),	7.13‐8.20	(m,	16H,	Ar‐
H),	 8.52	 (br.	 s,	 1H,	NH	 amide).	Anal.	 calcd.	 for	 C31H29N3O3:	 C,	
75.74;	H,	5.95;	N,	8.55.	Found:	C,	76.24;	H,	5.82;	N,	8.74%.	
(2S)‐N‐(2‐(5‐(4‐Chlorophenyl)‐3‐phenyl‐4,	 5‐dihydro‐1H‐
pyrazol‐1‐yl)‐2‐oxoethyl)‐2‐(6‐methoxynaphthalen‐2‐yl)propan	
amide	 (5b):	Color:	Off	white	powder.	Yield:	63%.	M.p.:	78‐80	
°C.	Rf:	A	=	0.65,	B	=	0.54.	FT‐IR	(KBr,	ν,	cm‐1):	3292	(NH	amide),	
1653	 (C=O	amide),	 1606	 (C=C	Aromatic),	 1541	 (C=N	amide),	
1265	 (Ar‐O‐C),	 813	 (C‐Cl).	 1H	 NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	
ppm):	 1.42‐1.44	 (d,	 3H,	 CH3	 naproxe),	 3.52‐3.71	 (m,	 3H,	 CH2	
pyrazoline	and	CH	of	naproxen),	3.86	(s,	3H,	‐OCH3	naproxen),	
4.00	 (br.s,	 2H,	 CH2	 glycine	 ),	 5.38	 (br.	 s,	 1H,	 CH	 pyrazoline),	
7.13‐7.99	(m,	13H,	Ar‐H),	8.09‐8.32	(m,	2H,	Ar‐H),	8.41	(br.	s,	
1H,	NH	amide).	Anal.	calcd.	for	C31H28ClN3O3:	C,	70.78;	H,	5.37;	
N,	7.99.	Found:	C,	71.98;	H,	5.24;	N,	8.19%.	
(2S)‐2‐(6‐Methoxynaphthalen‐2‐yl)‐N‐(2‐(5‐(4‐nitrophenyl)	
‐3‐phenyl‐4,	 5‐dihydro‐1H‐pyrazol‐1‐yl)‐2‐oxoethyl)propanami	
de	(5c):	Color:	Pale	orange	powder.	Yield:	61%.	M.p.:	85‐88	°C.	
Rf:	A	=	0.55,	B	=	0.45.	FT‐IR	(KBr,	ν,	cm‐1):	3294	(NH	amide),	
1658	 (C=O	amide),	 1604	 (C=C	Aromatic),	 1572	 (C=N	amide),	
1516	 (NO2	 asymmetric),	 1342	 (NO2	 symmetric),	 1265	 (Ar‐O‐
C).	1H	NMR	(500	MHz,	DMSO‐d6,	δ,	ppm):	1.41‐1.43	(d,	3H,	CH3	
naproxe),	 3.48‐3.71	 (m,	 3H,	 CH2	 pyrazoline	 and	 CH	 of	
naproxen),	 3.86	 (s,	 3H,	 ‐OCH3	 naproxen),	 4.00	 (br.s,	 2H,	 CH2	
glycine),	5.21	(br.	s,	1H,	CH	pyrazoline),	7.13‐8.30	(m,	15H,	Ar‐
H),	 8.41	 (br.	 s,	 1H,	NH	 amide).	Anal.	 calcd.	 for	 C31H28N4O5:	 C,	
69.39;	H,	5.	26;	N,	10.44.	Found:	C,	68.25;	H,	5.33;	N,	10.56%.	
(2S)‐N‐(2‐(5‐(4‐Hydroxyphenyl)‐3‐phenyl‐4,	5‐dihydro‐1H‐
pyrazol‐1‐yl)‐2‐oxoethyl)‐2‐(6‐methoxynaphthalen‐2‐yl)propan	
amide	(5d):	Color:	Light	brown	powder.	Yield:	58%.	M.p.:	87‐
89	 °C.	 Rf:	 A	 =	 0.70,	 B	 =	 0.58.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3298	 (NH	
amide),	 1649	 (C=O	amide),	 1604	 (C=C	Aromatic),	 1545	 (C=N	
amide),	1346	(O‐H),	1267	(Ar‐O‐C).	1H	NMR	(500	MHz,	DMSO‐
d6,	δ,	ppm):	1.41‐1.43	(d,	3H,	CH3	naproxe),	3.57‐3.74	(m,	3H,	
CH2	 pyrazoline	 and	 CH	 of	 naproxen),	 3.86	 (s,	 3H,	 ‐OCH3	
naproxen),	 4.27	 (br.s,	 2H,	 CH2	 glycine),	 5.20	 (br.	 s,	 1H,	 CH	
pyrazoline),	 6.66‐8.28	 (m,	 15H,	 Ar‐H),	 8.44	 (br.	 s,	 1H,	 NH	
amide),	 10.22	 (br.	 s,	 1H,	 OH).	 Anal.	 calcd.	 for	 C31H29N3O4:	 C,	
73.35;	H,	5.76;	N,	8.28.	Found:	C,	74.09;	H,	5.67;	N,	8.41%.	
(2S)‐2‐(6‐Methoxynaphthalen‐2‐yl)‐N‐(2‐(5‐(4‐methoxy	
phenyl)‐3‐phenyl‐4,	 5‐dihydro‐1H‐pyrazol‐1‐yl)‐2‐oxoethyl)	
propanamide	(5e):	Color:	Off	white	powder.	Yield:	68%.	M.p.:	
100‐102	 °C.	Rf:	A	=	0.62,	B	=	0.51.	FT‐IR	 (KBr,	 ν,	 cm‐1):	 3298	
(NH	 amide),	 1655	 (C=O	 amide),	 1604	 (C=C	 Aromatic),	 1573	
(C=N	amide),	 1261	 (Ar‐O‐C).	 1H	NMR	 (500	MHz,	DMSO‐d6,	 δ,	
ppm):	 1.42‐1.44	 (d,	 3H,	 CH3	 naproxe),	 3.58‐3.83	 (m,	 3H,	 CH2	
pyrazoline	and	CH	of	naproxen),	3.86	(s,	6H,	‐OCH3	naproxen,	
OCH3),	 4.00	 (br.s,	 2H,	 CH2	 glycine),	 5.25	 (br.	 s,	 1H,	 CH	
pyrazoline),	 7.14‐8.29	 (m,	 15H,	 Ar‐H),	 8.41	 (br.	 s,	 1H,	 NH	
amide).	Anal.	 calcd.	 for	C32H31N3O4:	C,	73.68;	H,	5.99;	N,	8.06.	
Found:	C,	74.79;	H,	6.13;	N,	8.25%.	
(2S)‐N‐(2‐(5‐(4‐(Dimethylamino)phenyl)‐3‐phenyl‐4,	5‐di	
hydro‐1H‐pyrazol‐1‐yl)‐2‐oxoethyl)‐	2‐(6‐methoxynaphthalen‐2‐
yl)	propanamide	(5f):	Color:	Orange	powder.	Yield:	54%.	M.p.:	
115‐117	 °C.	Rf:	A	=	0.59,	B	=	0.45.	FT‐IR	 (KBr,	 ν,	 cm‐1):	 3294	
(NH	 amide),	 1653	 (C=O	 amide),	 1603	 (C=C	 Aromatic),	 1523	
(C=N	amide),	 1267	 (Ar‐O‐C).	 1H	NMR	 (500	MHz,	DMSO‐d6,	 δ,	
ppm):	 1.43‐1.44	 (d,	 3H,	 CH3	 naproxe),	 2.99	 (s,	 6H,	 N(CH3)2),	
3.60‐3.76	(m,	3H,	CH2	pyrazoline	and	CH	of	naproxen),	3.86	(s,	
3H,	 ‐OCH3	naproxen),	4.29	 (br.s,	2H,	CH2	glycine),	 5.27	 (br.	 s,	
1H,	CH	pyrazoline),	7.14‐8.30	 (m,	15H,	Ar‐H),	8.47	 (br.	 s,	1H,	
NH	 amide).	 Anal.	 calcd.	 for	 C33H34N4O3:	 C,	 74.13;	 H,	 6.41;	 N,	
10.48.	Found:	C,	73.69;	H,	6.50;	N,	10.67%.	
	
2.2.	Pharmacology	
	
2.2.1.	Anti‐inflammatory	evaluation	study	
	
In	 vivo,	 acute	 anti‐inflammatory	 effects	 of	 the	 chemically	
synthesized	 compounds	 5a‐f	 were	 evaluated	 in	 egg‐white	
induced	 paw	 edema	 [36].	 Their	 evaluation	 for	 ant‐inflam‐
matory	 activity	 based	 on	 measuring	 the	 decreases	 of	 paw	
thickness.		
	
2.2.1.1.	Methods	
	
2.2.1.1.1.	Animals	
	
Albino	 rats	 of	 either	 sex	 weighing	 (170±10	 g)	 were	
supplied	 by	 Iraqi	 Center	 for	 Cancer	 and	 Medical	 Genetic	
Research	and	were	housed	in	College	of	Pharmacy,	University	
of	Al‐Mustansiriyah	under	standardized	conditions	for	10	days	
for	 acclimatization.	 Animals	 were	 fed	 commercial	 chaw	 and	
had	 free	 access	 to	 water.	 Animals	 were	 brought	 to	 the	
laboratory,	one	hour	before	the	experiment,	and	were	divided	
into	eight	groups	(each	group	consist	of	6	rats)	as	follows:	
Group	A:	 Six	 rats	 served	 as	 control	 and	 treated	with	 the	
vehicle	(propylene	glycol	50%,	v:v).	
Group	B:	 Six	 rats	 treated	 with	 (s)‐naproxen	 as	 reference	
substance	in	a	dose	of	50mg/kg	suspended	in	propylene	glycol	
[37,38].	
Group	 C‐H:	 Six	 rats/group	 treated	 with	 the	 tested	
compounds	5a‐f,	respectively	in	doses	that	determined	below,	
also	suspended	in	propylene	glycol.	
	
2.2.1.1.2.	Calculations	for	dose	determination	
	
50	mg	/	kg	/	230	=	Dose	/	M.Wt.	of	the	tested	compound	
((s)‐Naproxen	=	230.26	g/mol),	Table	2.	
	
2.2.1.1.3.	Experimental	design	
	
The	 anti‐inflammatory	 activity	 of	 the	 tested	 compounds	
was	studied	using	the	egg‐white	induced	edema	model.		
	
Mahdi	et	al.	/	European	Journal	of	Chemistry	6	(4)	(2015)	461‐467	 465	
 
	
Table	2.	Compounds	with	their	molecular	weight	and	dose.	
Compounds	 Molecular	weight,	g	 Dose	mg/kg	
(S)‐Naproxen	 230.26 50.00
5a	 491.59 106.74
5b	 526.03 114.22
5c	 536.58 116.51
5d	 507.58	 110.21	
5e	 521.60	 113.26	
5f	 534.65 116.09
	
	
Table	3.	The	anti‐inflammatory	effect	of	control,	naproxen	and	compounds	5a‐f	on	egg‐white	induced	paw	edema	in	rat	#.	
Compounds	 Time	(min)	
0	 30	 60	 120	 180	 240	 300	
Paw	
Thickness	
(mm)	/	n=6	
Control	 4.85±0.05	 5.83±0.06 6.58±0.06 6.96±0.03	 6.81±0.06 6.71±0.02	 5.39±0.01
Naproxen	 4.82±0.04	 5.72±0.05 6.51±0.05 5.81±0.05 *a	 5.44±0.06 *a 5.14±0.06	*a	 4.93±0.02 *
5a	 4.87±0.06	 5.74±0.02 6.56±0.06 6.31±0.01 *b	 5.72±0.03 *b 5.43±0.02	*b	 5.06±0.04 *
5b	 4.81±0.03	 5.75±0.06 6.51±0.01 6.21±0.04 *b	 5.76±0.06 *b 5.51±0.02	*b	 4.99±0.05 *
5c	 4.81±0.02	 5.75±0.01	 6.50±0.03	 6.17±0.06	*b	 5.73±0.05	*b	 5.47±0.06	*b	 5.03±0.06	*	
5d	 4.78±0.01	 5.79±0.06 6.49±0.04 5.84±0.03 *a	 5.46±0.02 *a	 5.16±0.05	*a	 5.06±0.06 *
5e	 4.82±0.06	 5.74±0.02	 6.49±0.03	 5.91±0.02	*a	 5.41±0.04	*a	 5.15±0.01	*a	 4.99±0.06	*	
5f	 4.84±0.01	 5.82±0.02 5.77±0.04 *	 5.43±0.05 *c	 5.08±0.06 *c 4.86±0.03	*c	 4.94±0.08 *
#	Non‐identical	superscripts	(a,	b	and	c)	among	different	tested	compounds	are	considered	significantly	different	(p	<	0.05).	
*	Significantly	different	compared	to	control	(p	<	0.05).	Data	are	expressed	in	mm	paw	thickness	as	mean	±	SEM.	n=	number	of	animals.	Time	(0)	is	the	time	of	
i.p.	injection	of	naproxen,	tested	compounds	and	propylene	glycol.	Time	(30)	is	the	time	of	injection	of	egg	white	(induction	of	paw	edema).	
	
	
The	paw	thickness	was	measured	by	vernea	at	seven	time	
intervals	 (0,	 30,	 60,	 120,	 180,	 240,	 and	 300	min)	 after	 drug	
administration.	 Acute	 inflammation	 was	 produced	 by	 a	 sub‐
cutaneous	injection	of	0.05	mL	of	undiluted	egg‐white	into	the	
plantar	side	of	the	left	hind	paw	of	the	rats;	30	min	after	intra‐
peritoneal	administration	of	the	drugs	or	their	vehicle.	
	
2.2.1.2.	Statistical	analysis	
	
The	 data	 was	 expressed	 as	 the	 mean±standard	 error	 of	
mean	 (SEM)	 and	 results	 were	 analyzed	 for	 statistical	
significance	using	student	t‐test	(Two	sample	assuming	equal	
variances)	 for	 comparison	 between	 mean	 values.	 While	
comparisons	 between	 different	 groups	 were	 made	 using	
ANOVA:	Two	factors	without	replication.	Probability	(P)	value	
of	less	than	0.05	was	considered	significant.	
	
2.2.2.	Antimicrobial	activity	
	
A	 preliminary	 antibacterial	 activity	 has	 been	 carried	 out	
according	to	Well	Diffusion	Method:	The	prepared	compounds	
have	 been	 studied	 for	 their	 antimicrobial	 activity	 in	 vitro	
against	four	tested	bacteria	(Staphylococcus	aureus,	Bacillus,	as	
Gram	 positive	 bacteria	 and	 Pseudomonas	 aeruginosa,	
Escherichia	 coli,	 as	 Gram	 negative	 bacteria)	 were	 clinically	
activated	and	maintained	on	nutrient	agar	medium	for	testing	
the	 antibacterial	 activity.	 Naproxen	 was	 used	 as	 a	 reference	
drug	for	antibacterial	activity.	
	
2.2.2.1.	Sensitivity	assay	
	
Well	 diffusion	 assay	 was	 carried	 out	 by	 using	 bacterial	
suspension	of	about	1.5×106	CFU/mL	with	 turbidity	standard	
(number	 0.5).	 This	 was	 used	 to	 inoculate	 by	 swabbing	 the	
surface	of	Mueller	Hinton	agar	(MHA)	plates.	Excess	liquid	was	
air‐dried	 under	 a	 sterile	 hood.	 In	 each	 agar	 plate	 of	 tested	
bacteria	 four	 wells	 were	 made	 and	 100	 μL	 of	 each	
concentration	was	added	in	it.	The	plates	were	incubated	at	37	
°C	 for	 24	 hrs.	 The	 assessment	 of	 antibacterial	 activity	 were	
based	 on	 measurement	 of	 the	 diameter	 of	 inhibition	 zone	
formed	 around	 the	 well	 [39]	 thus,	 showed	 that	 the	 zone	 of	
inhibition	 mostly	 increased	 with	 the	 increasing	 of	
concentration	of	the	tested	compounds.	
	
3.	Result	and	discussions	
	
3.1.	Anti‐inflammatory	evaluation	study	
3.1.1.	The	anti‐inflammatory	activity	evaluation	of	the	
tested	compounds	
	
The	 anti‐inflammatory	 activity	 of	 the	 tested	 compounds	
has	been	evaluated	 in	 comparison	with	 their	vehicle	 (control	
group)	 and	 naproxen.	 Table	 3	 explains	 the	 effect	 of	 tested	
compounds	5a‐f	in	comparison	to	control	and	naproxen.		
	
3.1.2.	Comparative	study	
	
All	tested	compounds	exerted	significant	reduction	of	paw	
edema	in	comparison	to	the	effect	of	propylene	glycol	50%v/v	
(control	 group).	 The	 effect	 of	 naproxen	 and	 all	 tested	
compounds	started	at	time	120	min	except	5f	which	has	been	
started	at	60	min.	thus,	indicate	fast	onset	of	action.	The	effect	
of	tested	compounds	and	naproxen	continued	until	the	end	of	
experiment.	 Compound	5d	 and	5e	 showed	comparable	 effect	
to	naproxen	at	all	experimental	time	while	compounds	5a,	5b	
and	 5c	 produced	 significantly	 lower	 inhibitory	 effect	 than	
naproxen	 at	 time	 120‐240	 min.	 Surprisingly,	 compound	 5f	
exert	significantly	higher	paw	edema	reduction	than	naproxen	
at	 60‐240	 min.	 All	 tested	 compounds	 have	 been	 showed	
comparable	effect	to	that	of	naproxen	at	time	300	min.	
	
3.1.3.	Percent	of	inhibition	in	paw	edema	thickness	
	
The	percent	of	 inhibition	of	paw	edema	thickness	at	each	
time	 interval	was	 calculated	 from	 the	mean	 effect	 in	 control	
and	treated	animals	according	to	the	equation	[40]:	
	
%Inhibition=	[Vc	‐Vt	/Vc]	×100	 	 	 (1)	
	
Where	 Vc	 and	 Vt	 are	 the	mean	 paw	 thickness	 of	 the	 control	
group	 and	 tested	 group	 (at	 t‐time	 zero)	 respectively	 [40,41].	
The	 comparison	 among	 the	 naproxen,	 compounds	 5a‐f	 was	
shown	in	Table	4.	
	
3.2.	Antibacterial	activity	
	
Naproxen	and	ciprofloxacin	as	reference,	DMSO	as	control	
and	 the	synthesized	compounds	5a‐f	were	screened	 for	 their	
antibacterial	activity	studies	against	Pseudomonas	aeruginosa,	
Escherichia	 coli,	 Bacillus	 and	 Staphylococcus	 aureus	 at	
concentrations	 of	 62.5,	 125,	 250	 and	 500	 μg/mL	 except	 the	
control	which	used	pure.	Table	5	illustrates	the	inhibition	zone	
in	millimeter	for	each	concentration	of	all	tested	compounds.		
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Table	4.	Percent	inhibition	of	naproxen,	compounds	5a‐f	on	egg‐white	induced	paw	edema	in	rats.	
Time	(min)	 Percent	of	inhibition,	%	
Naproxen	 5a	 5b 5c 5d 5e	 5f
60	 2.3	 2.3	 1.7 3.2 1.1 3.4	 46.2
120	 53.0		 31.7	 33.6 35.5 49.7 48.3	 72.0
180	 68.3	 56.6	 51.5 53.0 65.3 69.8	 87.7
240	 82.7	 69.8	 62.3 64.5 79.5 82.2	 98.9
300	 79.6	 64.8	 66.6 59.2 48.1 68.5	 81.4
	
	
Table	5.	Antibacterial	activity	of	synthesized	compounds	5a‐f.	
Compounds	and	standard	 Concentration	
(µg/mL)	
Zone	of	inhibition	(mm)	
Gram	negative Gram	positive	
Escherichia	coli Pseudomonas	aeruginosa Bacillus Staphylococcus	aureus
5a	 500.0	 20	 19	 29	 18	
250.0	 7	 19	 24	 10	
125.0	 12 14 23 7	
62.5	 ‐	 ‐	 23	 ‐	
5b	 500.0	 16 20 23 21	
250.0	 12	 21	 25	 12	
125.0	 7 10 19 ‐	
62.5	 7 8 17 ‐	
5c	 500.0	 13	 17	 21	 16	
250.0	 10 14 20 8	
125.0	 9	 13	 19	 8	
62.5	 10 12 15 ‐	
5d	 500.0	 15	 19	 24	 15	
250.0	 13	 14	 24	 13	
125.0	 11 10 26 10	
62.5	 11	 ‐	 20	 8	
5e	 500.0	 23 25 32 14	
250.0	 15 15 20 7	
125.0	 11 11
62.5	 11 7 16 -	
5f	 500.0	 16	 22	 22	 20	
250.0	 15 20 20 16	
125.0	 13	 15	 20	 14	
62.5	 13 11 20 ‐	
Naproxen	 500.0	 ‐ 12 ‐ ‐	
250.0	 ‐ ‐ ‐ ‐	
125.0	 ‐ ‐ 14 ‐	
62.5	 ‐	 ‐	 ‐	 ‐	
Ciprofloxacin	 500.0	 35 18 26 25	
250.0	 33	 23	 30	 25	
125.0	 30 19 26 25	
62.5	 28 13 26 25	
DMSO	 Pure	 ‐	 ‐	 ‐	 ‐	
	
	
In	 general,	 all	 tested	 compounds	 showed	 an	 interesting	
activity	 against	 Gram	 positive	 and	 Gram	 negative	 bacteria	
especially	 Bacillus,	 Staphylococcus	 aureus,	 Pseudomonas	
aeruginosaand	Escherichia	coli.	These	tested	compounds	exert	
significant	 antibacterial	 activity	 in	 comparison	 to	 DMSO	 as	
control	 group.	 In	 comparison	 to	 standard	 compound	
(Ciprofloxacin),	 tested	 compound	 exert	 lower	 effect	 against	
Escherichia	 coli	 and	 nearly	 comparable	 effect	 against	
Pseudomonas	aeruginosa.	Also,	 the	tested	compounds	showed	
a	 comparable	 antibacterial	 effect	 against	 Bacillus	 and	 lower	
activity	 against	 Staphylococcus	 aureus.	 In	 comparison	 the	
antibacterial	results	among	the	tested	compounds	5e	might	be	
considered	 as	 the	 most	 effective	 one	 and	 5c	 as	 the	 lower	
effective	one	which	might	lead	to	the	conclusion	that	electron	
withdrawing	 substitutes	 have	 generally	 lower	 antibacterial	
effect	than	electron	donating	substitutes.	
	
4.	Conclusions	
	
Anti‐inflammatory	 study	 that	 has	 been	 used	 egg‐white	
induced	 edema	model	 of	 inflammation	 has	 been	 shown	 that	
the	 incorporation	 of	 pyrazoline	 pharmacophore	 into	 a	
naproxen	 maintained	 or	 enhanced	 it	 is	 anti‐inflammatory	
activity.	 Furthermore	 the	 antibacterial	 activity	 has	 been	
studied	 by	well	 diffusion	method	 showed	 significant	 activity	
against	 Gram	 positive	 and	 Gram	 negative	 bacteria	 especially	
Bacillus,	 Staphylococcus	 aureus,	 Pseudomonas	 aeruginosaand	
Escherichia	coli.	
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